These samples were also analyzed for KRAS mutations because (i) EGFR and KRAS mutations are mutually exclusive in NSCLC and (ii) emerging data suggest that KRAS mutations are negative predictors of benefit from both adjuvant chemotherapy and anti-EGFR-directed therapies [12,14,15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.